-
1.发明申请OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS 审中-公开奥沙利多和噻唑烷酮化合物及其作为NICOTINIC乙酰胆碱受体调节剂公开(公告)号：US20100029685A1
公开(公告)日：2010-02-04
申请号：US12447205
申请日：2007-10-24
IPC分类号： A61K31/4965 , C07D271/07 , C07D401/14 , C07D285/08 , C07D413/04 , C07D417/04 , A61K31/4439 , A61K31/4155 , A61P25/28 , A61P25/02
CPC分类号： C07D413/14 , C07D285/12 , C07D285/135 , C07D413/04 , C07D417/04
摘要： This invention relates to oxadiazolyl and thiadiazolyl derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
摘要翻译： 本发明涉及恶二唑基和噻二唑基衍生物，其被发现是烟碱型乙酰胆碱受体的调节剂。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。
-
公开(公告)号：US08017631B2
公开(公告)日：2011-09-13
申请号：US11919146
申请日：2006-04-24
IPC分类号： A61K31/4245 , C07D413/04
CPC分类号： C07D413/04 , C07D413/14 , C07D417/14
摘要： This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
摘要翻译： 本发明涉及新的恶二唑衍生物，其被发现是烟碱乙酰胆碱受体的调节剂。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。
-
公开(公告)号：US20090312347A1
公开(公告)日：2009-12-17
申请号：US11919146
申请日：2006-04-24
IPC分类号： A61K31/4245 , A61K31/497 , A61K31/437 , C07D413/14 , C07D413/04 , A61P25/00
CPC分类号： C07D413/04 , C07D413/14 , C07D417/14
摘要： This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
摘要翻译： 本发明涉及新的恶二唑衍生物，其被发现是烟碱乙酰胆碱受体的调节剂。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。
-
4.发明申请PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER 审中-公开非甾体类受体调节剂和认知增强剂的药物组合公开(公告)号：US20100234349A1
公开(公告)日：2010-09-16
申请号：US12303927
申请日：2007-09-04
申请人： Gunnar M. Olsen , Dan Peters , Bjarne H. Dahl , Jeppe Kejser Christensen , Steven Charles Loechel , Daniel B. Timmermann
发明人： Gunnar M. Olsen , Dan Peters , Bjarne H. Dahl , Jeppe Kejser Christensen , Steven Charles Loechel , Daniel B. Timmermann
IPC分类号： A61K31/554 , A61K31/55 , A61K31/551 , A61K31/5415 , A61K31/4985 , A61K31/496 , A61K31/497 , A61K31/519 , A61K31/48 , A61K31/473 , A61K31/445 , A61K31/4525 , A61K31/454 , A61K31/451 , A61K31/4439 , A61K31/4406 , A61K31/4245 , A61K31/428 , A61K31/4015 , A61K31/38 , A61K31/343 , A61K31/27 , A61K31/195 , A61K31/17 , A61K31/15 , A61K31/136 , A61K31/138 , A61P25/18 , A61K31/465 , A61P25/00 , A61P25/16 , A61P25/24 , A61P25/22
CPC分类号： A61K45/06 , A61K31/4245 , A61K31/4439 , A61K31/445 , A61K31/4523 , A61K31/465 , A61K31/497 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K2300/00
摘要： This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.
摘要翻译： 本发明涉及包含尼古丁受体的正变构调节剂的治疗有效组合的新型药物组合物; 以及选自尼古丁乙酰胆碱受体激动剂，乙酰胆碱酯酶抑制剂，阳性AMPA受体调节剂，抗精神病药物，抗抑郁药物和抗帕金森药物的认知增强剂。 预期根据本发明使用的药物组合物特别可用于对抗认知障碍。
-
5.发明申请2,5-DISUBSTITUTED TETRAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS 审中-公开2,5-取代的四唑衍生物及其作为NICOTINIC乙酰胆碱受体调节剂的用途公开(公告)号：US20120095056A1
公开(公告)日：2012-04-19
申请号：US13257065
申请日：2010-03-17
IPC分类号： A61K31/4439 , A61P25/00 , A61P25/28 , A61P25/16 , A61P25/24 , A61P25/22 , A61P25/04 , A61P25/18 , A61P25/14 , A61P11/06 , A61P1/12 , A61P9/12 , A61P1/00 , A61P17/10 , A61P15/10 , A61P15/12 , A61P25/08 , A61P3/04 , A61P25/06 , A61P9/06 , A61P29/00 , A61P25/30 , A61P25/34 , A61P25/32 , A61P25/36 , C07D401/04
CPC分类号： C07D401/04
摘要： This invention relates to novel tetrazole derivatives of formula (I), which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro- degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
摘要翻译： 本发明涉及式（I）的新型四唑衍生物，其被发现是烟碱型乙酰胆碱受体的调节剂。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩，内分泌疾病或病症，与由于终止化学物质的滥用而引起的炎症，疼痛和戒断症状相关的神经变性，疾病或病症相关的疾病或病症。
-
![3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors](/abs-image/US/2011/08/02/US07989470B2/abs.jpg.150x150.jpg)
6.发明授权3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors 失效3,8-取代的8-氮杂 - 双环[3.2.1]辛烷衍生物及其作为单胺神经递质再摄取抑制剂的用途公开(公告)号：US07989470B2
公开(公告)日：2011-08-02
申请号：US12727972
申请日：2010-03-19
申请人： Dan Peters , Bjarne H. Dahl , Gunnar M. Olsen , Elsebet Ostergaard Nielsen , Jorgen Scheel-Kruger , John Paul Redrobe
发明人： Dan Peters , Bjarne H. Dahl , Gunnar M. Olsen , Elsebet Ostergaard Nielsen , Jorgen Scheel-Kruger , John Paul Redrobe
IPC分类号： A61K31/46 , C07D451/02
CPC分类号： C07D451/06
摘要： This invention relates to novel 8-aza-bicyclo[3.2.1]octane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
摘要翻译： 本发明涉及可用作单胺神经递质再摄取抑制剂的新型8-氮杂 - 双环[3.2.1]辛烷衍生物。 在其它方面，本发明涉及这些化合物在治疗方法中的用途以及包含本发明化合物的药物组合物。
-
7.发明授权Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors 失效烷基取代的高哌嗪衍生物及其作为单胺神经递质再摄取抑制剂的用途公开(公告)号：US07923444B2
公开(公告)日：2011-04-12
申请号：US11795768
申请日：2006-02-09
申请人： Dan Peters , Bjarne H. Dahl , Gunnar M. Olsen , Elsebet Oestergaard Nielsen , Jørgen Scheel-Kruger , John Paul Redrobe
发明人： Dan Peters , Bjarne H. Dahl , Gunnar M. Olsen , Elsebet Oestergaard Nielsen , Jørgen Scheel-Kruger , John Paul Redrobe
IPC分类号： A61P25/00 , A61K31/551 , C07D243/08 , C07D401/04
CPC分类号： C07D401/04 , C07D243/08
摘要： This invention relates to novel alkyl substituted homopiperazine derivatives useful as monoamine neurotransmitter re-uptake inhibitors.In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
摘要翻译： 本发明涉及可用作单胺神经递质再摄取抑制剂的新型烷基取代的高哌嗪衍生物。 在其它方面，本发明涉及这些化合物在治疗方法中的用途以及包含本发明化合物的药物组合物。
-
8.发明申请Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors 审中-公开新型对映异构体及其作为单胺神经递质重吸收抑制剂的用途公开(公告)号：US20090137625A1
公开(公告)日：2009-05-28
申请号：US11887246
申请日：2006-04-06
申请人： Dan Peters , Bjarne H. Dahl , Dorthe Filtenborg Olesen , Elsebet Ostergaard Nielsen , Gunnar M. Olsen , John Paul Redrobe
发明人： Dan Peters , Bjarne H. Dahl , Dorthe Filtenborg Olesen , Elsebet Ostergaard Nielsen , Gunnar M. Olsen , John Paul Redrobe
IPC分类号： A61K31/46 , C07D451/02 , A61P25/00 , A61P25/24 , A61P25/28 , A61P25/16 , A61P25/22 , A61P25/06 , A61P25/18 , A61P29/00
CPC分类号： C07D451/02 , C07B2200/07
摘要： This invention relates to novel enantiomers useful as monoamine neurotransmitter re-uptake inhibitors.In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
摘要翻译： 本发明涉及可用作单胺神经递质再摄取抑制剂的新型对映异构体。 在其它方面，本发明涉及这些化合物在治疗方法中的用途以及包含本发明化合物的药物组合物。
-
9.发明申请Novel Alkyl Substituted Homopiperazine Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors 失效新型烷基取代的高哌嗪衍生物及其作为单胺神经递质重吸收抑制剂公开(公告)号：US20080132489A1
公开(公告)日：2008-06-05
申请号：US11795768
申请日：2006-02-09
申请人： Dan Peters , Bjarne H. Dahl , Gunnar M. Olsen , Elsebet Ostergaard Nielsen , Jorgen Scheel-Kruger , John Paul Redrobe
发明人： Dan Peters , Bjarne H. Dahl , Gunnar M. Olsen , Elsebet Ostergaard Nielsen , Jorgen Scheel-Kruger , John Paul Redrobe
IPC分类号： A61K31/551 , C07D243/08 , A61P25/28 , A61P25/16 , A61P25/24
CPC分类号： C07D401/04 , C07D243/08
摘要： This invention relates to novel alkyl substituted homopiperazine derivatives useful as monoamine neurotransmitter re-uptake inhibitors.In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
摘要翻译： 本发明涉及可用作单胺神经递质再摄取抑制剂的新型烷基取代的高哌嗪衍生物。 在其它方面，本发明涉及这些化合物在治疗方法中的用途以及包含本发明化合物的药物组合物。
-
10.发明申请TRIAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS 审中-公开三唑衍生物及其作为NICOTINIC乙酰胆碱受体调节剂公开(公告)号：US20110212999A1
公开(公告)日：2011-09-01
申请号：US13061416
申请日：2009-09-01
IPC分类号： A61K31/4192 , C07D401/04 , C07D401/14 , C07D249/06 , C07D405/14 , A61K31/4439 , A61K31/444 , A61P25/00 , A61P25/28 , A61P25/18 , A61P25/24 , A61P25/16 , A61P25/08 , A61P25/14 , A61P25/30 , A61P9/06 , A61P9/10 , A61P15/06 , A61P1/04 , A61P1/12
CPC分类号： C07D401/04 , C07D407/14
摘要： This invention relates to novel triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
摘要翻译： 本发明涉及新的三唑衍生物，其被发现是烟碱乙酰胆碱受体的调节剂。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。
-
-
-
-
-
-
-
-
-
搜索结果
294 条记录 (耗时 0.032 秒)
